Decreased brain serotonin transporter binding in the euthymic state of bipolar I but not bipolar II disorder: A SPECT study

Bipolar Disorders

Volumn 12, Issue 3, 2010, Pages 312-318

  Chou, Yuan Hwa ^a   Wang, Shyh Jen ^b   Lin, Chun Lung ^c   Mao, Wei Chung ^d   Lee, Shin Min ^e   Liao, Mei Hsiu ^f  

^a Department of Psychiatry ^*  (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c TAOYUAN ARMED FORCES GENERAL HOSPITAL   (Taiwan)

^d TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^e Yuli Hospital Department of Health Taiwan   (Taiwan)

^f INSTITUTE OF NUCLEAR ENERGY RESEARCH   (Taiwan)

Author keywords

^{123< sup>I ADAM; Bipolar I disorder; Bipolar II disorder; Euthymic state; Serotonin transporter; SPECT}

Indexed keywords

2 [[2 [(DIMETHYLAMINO)METHYL]PHENYL]THIO] 5 IODOPHENYLAMINE I 123; AMFEBUTAMONE; ESTAZOLAM; OLANZAPINE; QUETIAPINE; RISPERIDONE; SEROTONIN TRANSPORTER; TRACER; UNCLASSIFIED DRUG; VALPROIC ACID; ZOLPIDEM; 2-((2-((DIMETHYLAMINO)METHYL)PHENYL)THIO)-5-IODOPHENYLAMINE; ANTIDEPRESSANT AGENT; CINANSERIN; NEUROLEPTIC AGENT; PROTEIN BINDING; RADIOACTIVE IODINE; SEROTONIN ANTAGONIST;

ADULT; AGE; ARTICLE; BIPOLAR I DISORDER; BIPOLAR II DISORDER; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE DURATION; FEMALE; HOSPITALIZATION; HUMAN; MALE; MESENCEPHALON; MONOTHERAPY; MONTGOMERY ASBERG DEPRESSION RATING SCALE; PRIORITY JOURNAL; PROTEIN BINDING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; YOUNG MANIA RATING SCALE; ANALOGS AND DERIVATIVES; ANALYSIS OF VARIANCE; BIPOLAR DISORDER; BRAIN; CLASSIFICATION; DIAGNOSTIC USE; DRUG EFFECTS; METABOLISM; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PHYSIOLOGY; PROCEDURES; PSYCHOLOGICAL RATING SCALE; SCINTISCANNING;

ANALYSIS OF VARIANCE; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; BRAIN; CINANSERIN; HUMANS; IODINE RADIOISOTOPES; MAGNETIC RESONANCE IMAGING; PROTEIN BINDING; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN ANTAGONISTS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 77953939676     PISSN: 13985647     EISSN: 13995618     Source Type: Journal    
DOI: 10.1111/j.1399-5618.2010.00800.x     Document Type: Article

References (44)

1. Shiah I-S, Yatham LN. Serotonin in mania and in the mechanism of action of mood stabilizers: a review of clinical studies. Bipolar Disord 2000, 2:77-92.
2. Sobczak S, Honig A, van Duinen MA, Riedel WJ. Serotonergic dysregulation in bipolar disorders: a literature review of serotonergic challenge studies. Bipolar Disord 2002, 4:347-356.
3. Farde L, Hall H, Ehrin E, Sedvall G. Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET. Science 1986, 231:258-261.
4. Wagner HN, Burns HD, Dannals RF. Imaging dopamine receptors in the human brain by positron tomography. Science 1983, 221:1264-1266.
5. Houle S, Ginovart N, Hussey D, Meyer JH, Wilson AA. Imaging the serotonin transporter with positron emission tomography: initial human studies with [11C]DAPP and [11C]DASB. Eur J Nucl Med 2000, 27:1719-1722.
6. Catafau AM, Perez V, Penengo MM. SPECT of serotonin transporters using 123I-ADAM: optimal imaging time after bolus injection and long-term test-retest in healthy volunteers. J Nucl Med 2005, 46:1301-1309.
7. Oquendo MA, Hastings RS, Huang Y-Y. Brain serotonin transporter binding in depressed patients with bipolar disorder using positron emission tomography. Arch Gen Psychiatry 2007, 64:201-208.
8. Cannon DM, Ichise M, Fromm SJ. Serotonin transporter binding in bipolar disorder assessed using [11C]DASB and positron emission tomography. Biol Psychiatry 2006, 60:207-217.
9. Cannon DM, Ichise M, Rollis D. Elevated serotonin transporter binding in major depressive disorder assessed using positron emission tomography and [11C]DASB; comparison with bipolar disorder. Biol Psychiatry 2007, 62:870-877.
10. Judd LL, Akiskal HS, Schettler PJ. Psychosocial disability in the course of bipolar I and II disorders: a prospective, comparative, longitudinal study. Arch Gen Psychiatry 2005, 62:1322-1330.
11. Berk M, Conus P, Lucas N. Setting the stage: from prodrome to treatment resistance in bipolar disorder. Bipolar Disord 2007, 9:671-678.
12. Phillips ML, Travis MJ, Fagiolini A, Kupfer DJ. Medication effects in neuroimaging studies of bipolar disorder. Am J Psychiatry 2008, 165:313-320.
13. Sheline YI. Neuroimaging studies of mood disorder effects on the brain. Biol Psychiatry 2003, 54:338-352.
14. Tolmunen T, Joensuu M, Saarinen PI. Elevated midbrain serotonin transporter availability in mixed mania: a case report. BMC Psychiatry 2004, 4:27.
15. Diagnostic and Statistical Manual of Mental Disorders 1994, 4th edition, Washington DC, American Psychiatric Association
16. Diagnostic and Statistical Manual of Mental Disorders 1987, 3rd edition revised, Washington, DC, American Psychiatric Association
17. The International Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guideline 1992, 10th edition, Geneva, World Health Organization
18. Roth BL, Hanizavareh SM, Blum AE. Serotonin receptors represent highly favorable molecular targets for cognitive enhancement in schizophrenia and other disorders. Psychopharmacology 2004, 174:17-24.
19. Newberg AB, Plossl K, Mozley PD. Biodistribution and imaging with (123)I-ADAM: a serotonin transporter imaging agent. J Nucl Med 2004, 45:834-841.
20. Oya S, Choi SR, Hou C. 2-((2-((dimethylamino)methyl)phenyl)thio)-5-iodophenylamine (ADAM): an improved serotonin transporter ligand. Nucl Med Biol 2000, 27:249-254.
21. Chou YH, Yang BH, Chung MY. Imaging the serotonin transporter using 123I-ADAM in the human brain. Psychiatry Res 2009, 172:38-43.
22. Acton PD, Choi SR, Hou C, Plossl K, Kung HF. Quantification of serotonin transporters in nonhuman primates using [(123)I]ADAM and SPECT. J Nucl Med 2001, 42:1556-1562.
23. Erlandsson K, Sivananthan T, Lui D. Measuring SSRI occupancy of SERT using the novel tracer [123I]ADAM: a SPECT validation study. Eur J Nucl Med Mol Imaging 2005, 32:1329-1336.
24. Sheehan DV, Lecrubier Y, Sheehan KH. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998, 59:22-33.
25. Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. B J Psychiatry 1979, 134:382-389.
26. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978, 133:429-435.
27. Choi SR, Hou C, Oya S. Selective in vitro and in vivo binding of [(125)I]ADAM to serotonin transporters in rat brain. Synapse 2000, 38:403-412.
28. Ashburner J, Friston KJ. Nonlinear spatial normalization using basis functions. Hum Brain Mapp 1999, 7:254-266.
29. Ashburner J, Andersson JL, Friston KJ. Image registration using a symmetric prior - in three dimensions. Hum Brain Mapp 2000, 9:212-225.
30. Chou YH, Huang WS, Su TP, Lu RB, Wan FJ, Fu YK. Dopamine transporters and cognitive function in methamphetamine abuser after a short abstinence: A SPECT study. Eur Neuropsychopharmacol 2007, 17:46-52.
31. Chou YH, Karlsson P, Halldin C, Olsson H, Farde L. A PET study of D(1)-like dopamine receptor ligand binding during altered endogenous dopamine levels in the primate brain. Psychopharmacology 1999, 146:220-227.
32. Vieta E, Suppes T. Bipolar II disorder: arguments for and against a distinct diagnostic entity. Bipolar Disord 2008, 10:163-178.
33. Summers M, Papadopoulou K, Bruno S, Cipolotti L, Ron MA. Bipolar I and bipolar II disorder: cognition and emotion processing. Psychol Med 2006, 36:1799-1809.
34. Sun Y, Zhang L, Johnston NL, Torrey EF, Yolken RH. Serial analysis of gene expression in the frontal cortex of patients with bipolar disorder. Br J Psychiatry 2001, 41:s137-s141.
35. Friedman JNW, Hurley RA, Taber KH. Bipolar disorder: imaging state versus trait. J Neuropsychiatry Clin Neurosci 2006, 18:296-301.
36. Judd LL, Schettler PJ, Akiskal HS. Long-term symptomatic status of bipolar I vs. bipolar II disorders. Int J Neuropsychopharmacol 2003, 6:127-137.
37. Judd LL, Akiskal HS, Schettler PJ. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry 2003, 60:261-269.
38. Vieta E, Sanchez-Moreno J, Lahuerta J, Zaragoza S, Group E. Subsyndromal depressive symptoms in patients with bipolar and unipolar disorder during clinical remission. J Affect Disord 2008, 107:169-174.
39. Torrent C, Martinez-Aran A, Daban C. Cognitive impairment in bipolar II disorder. Br J Psychiatry 2006, 189:254-259.
40. Mur M, Portella MJ, Martinez-Aran A, Pifarre J, Vieta E. Long-term stability of cognitive impairment in bipolar disorder: a 2-year follow-up study of lithium-treated euthymic bipolar patients. J Clin Psychiatry 2008, 69:712-719.
41. Frokjaer VG, Pinborg LH, Madsen J. Evaluation of the serotonin transporter ligand 123I-ADAM for SPECT studies on humans. J Nucl Med 2008, 49:247-254.
42. Vieta E, Gasto C, Otero A, Nieto E, Vallejo J. Differential features between bipolar I and bipolar II disorder. Compr Psychiatry 1997, 38:98-101.
43. Tarazi FI, Zhang K, Baldessarini RJ. Olanzapine, quetiapine, and risperidone: long-term effects on monoamine transporters in rat forebrain. Neurosci Lett 2000, 287:81-84.
44. Tatsumi M, Jansen K, Blakely RD, Richelson E. Pharmacological profile of neuroleptics at human monoamine transporters. Eur J Pharmacol 1999, 368:277-283.